Guidance includes a negative currency impact for FY23 of approximately $2.2M versus prior year. This 2023 guidance includes approximately $75M-$85M of PDN indication sales, an increase of 56% to 77% over prior year. The company expects full-year 2023 non-GAAP adjusted EBITDA to be a loss of approximately $5M-$10M, which compares to a non-GAAP adjusted EBITDA loss of $23.8M in 2022.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on NVRO:
- Nevro Announces Fourth Quarter and Full-Year 2022 Financial Results and Provides First Quarter and Complete Full-Year 2023 Guidance
- Nevro price target raised to $72 from $67 at Canaccord
- Abbott approval ‘incremental headwind’ to Nevro, says Piper Sandler
- Nevro price target lowered to $37 from $38 at Piper Sandler
- Nevro downgraded to Neutral from Buy at Citi
